Vertex Triple-Data Combos Live Up To High Hopes In Early Studies
Phase I and II results for three of Vertex's four next-generation CFTR correctors showed positive effects on pulmonary function when added to two of the company's approved cystic fibrosis therapies. The drugs are moving rapidly forward so that one or two can move into pivotal trials in 2018.
You may also be interested in...
Vertex duplicated promising efficacy observed in Phase II for its cystic fibrosis triple combo that includes VX-659, but wants to see data expected in early 2019 for a triplet containing VX-445 before filing for approvals.
Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.
Positive topline data from the ALBATROSS Phase II study suggest Galapagos's GLPG2222 is well tolerated and could bring additional therapeutic benefits to cystic fibrosis patients.